Corticosteroids for community-acquired pneumonia: a critical view of the evidence

Chalmers James D.

Source: Eur Respir J 2016; 48: 984-986

Journal Issue: October

Disease area: Respiratory infections

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Chalmers James D.. Corticosteroids for community-acquired pneumonia: a critical view of the evidence. Eur Respir J 2016; 48: 984-986

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Corticosteroids for community-acquired pneumonia: are we still there? Source: International Congress 2019 – Severe pneumonia: epidemiology, mechanisms and treatment Year: 2019
Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006
Corticosteroids and community-acquired pneumonia Source: Annual Congress 2007 - Corticosteroids and respiratory failure Year: 2007
Corticosteroids in severe pneumonia Source: Eur Respir J 2008; 32: 259-264 Year: 2008
Another view on the prediction of outcomes in patients with community-acquired pneumonia Source: Eur Respir J 2011; 38: 992-993 Year: 2011
Another view on the prediction of outcomes in patients with community-acquired pneumonia Source: Eur Respir J 2011; 38: 991-992 Year: 2011
Community-acquired pneumonia guidelines: much guidance, but not much evidence Source: Eur Respir J 2002; 20: 1-3 Year: 2002
Should steroids be used in community-acquired pneumonia? Pro argument Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate Year: 2017
Lower respiratory tract infections: when are antibiotics mandatory? Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=146 Year: 2004
Low-dose corticosteroids during severe community-acquired pneumonia: end of the story Source: Eur Respir J 2015; 45: 305-307 Year: 2015
Treatment of severe community-acquired pneumonia: new horizons Source: International Congress 2014 – Advances in managing acute respiratory failure Year: 2014
Biomarkers in community-acquired pneumonia: still searching for the one Source: Eur Respir J, 53 (2) 1802469; 10.1183/13993003.02469-2018 Year: 2019
Should macrolides be given to all patients with community-acquired pneumonia? Pro argument Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate Year: 2017
Respiratory infections in the immunocompetent host: from asthma exacerbations to hospital-acquired pneumonia Source: Annual Congress 2007 - Infections year in review Year: 2007
Japanese guidelines for the management of community-acquired pneumonia: differential diagnosis of atypical pneumonia and bacterial pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 374s Year: 2006
Inhaled antibiotics in ventilator-associated pneumonia: treatment or prophylaxis? Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections Year: 2016
Increasing outpatient treatment of mild community-acquired pneumonia: systematic review and meta-analysis Source: Eur Respir J 2011; 37: 858-864 Year: 2011
COPD: what is the frequency and impact of community-acquired pneumonia? Source: Annual Congress 2008 - Community-acquired pneumonia and COPD: what do we know? Year: 2008
Clinical stability and switch therapy in hospitalised patients with community-acquired pneumonia: are we there yet? Source: Eur Respir J 2013; 41: 5-6 Year: 2013
Should macrolides be given to all patients with community-acquired pneumonia? Con argument Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate Year: 2017